<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189318</url>
  </required_header>
  <id_info>
    <org_study_id>D1443C00042</org_study_id>
    <nct_id>NCT01189318</nct_id>
  </id_info>
  <brief_title>Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder</brief_title>
  <official_title>Effects of Seroquel XR (Quetiapine Fumarate Extended-Release) on Sleep Architecture in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with major depressive disorder (MDD) who have insomnia symptom are&#xD;
      treated with Seroquel XR in an open-label manner for a 4-week period with repeated&#xD;
      measurements of insomnia symptoms and sleep parameters using polysomnography.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline Pittsburgh Quality Index total scores at 4 weeks</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline Pittsburgh Quality Index total scores at 2 weeks</measure>
    <time_frame>baseline and 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline Pittsburgh Quality Index total scores at 4 days</measure>
    <time_frame>baseline and 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in sleep architecture measured using polysomnography at 4 weeks</measure>
    <time_frame>baseline and at 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Seroquel XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MDD receives Seroquel XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine Fumarate Extended Release</intervention_name>
    <description>Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)</description>
    <arm_group_label>Seroquel XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 20 and 65&#xD;
&#xD;
          -  Diagnosis of major depressive disorder as assessed by Structured Clinical Interview&#xD;
             for DSM-IV (SCID-IV)&#xD;
&#xD;
          -  A score of 1 or greater on any of the sleep items (items 4, 5, 6) from the Hamilton&#xD;
             Depression Rating Scale (HDRS)&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
        Healthy Control Subject Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Men and Women aged between 20 and 65&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any major physical or neurological illness (e.g.，head trauma，&#xD;
             epilepsy，seizure，stroke，cerebral tumor，multiple sclerosis，cerebrovascular disease,&#xD;
             narrow-angle glaucoma, drug hypersensitivity，etc.)&#xD;
&#xD;
          -  Diagnosis of any Axis I disorder other than major depressive disorder or presence of&#xD;
             symptoms requiring hospitalization&#xD;
&#xD;
          -  Drug abuse in past 3 months&#xD;
&#xD;
          -  Women who are pregnant，breastfeeding, or planning pregnancy&#xD;
&#xD;
          -  Contraindications to drugs used in the study (e.g., allergy, intolerance, etc.)&#xD;
&#xD;
          -  Unstable medical illness or severe abnormality in laboratory test at screening&#xD;
             assessment&#xD;
&#xD;
          -  Increase in blood glucose, lipid, and calcium levels at screening&#xD;
&#xD;
          -  Low blood pressure at screening assessment&#xD;
&#xD;
          -  Intelligence quotient below 80&#xD;
&#xD;
          -  Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding&#xD;
             enrolment including but not limited to: ketoconazole, itraconazole, fluconazole,&#xD;
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,&#xD;
             fluvoxamine and saquinavir&#xD;
&#xD;
          -  Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding&#xD;
             enrolment including but not limited to: phenytoin, carbamazepine, barbiturates,&#xD;
             rifampin, St. John's Wort, and glucocorticoids&#xD;
&#xD;
          -  Administration of a depot antipsychotic injection within one dosing interval (for the&#xD;
             depot) before randomisation&#xD;
&#xD;
          -  Substance or alcohol dependence at enrolment (except dependence in full remission, and&#xD;
             except for caffeine or nicotine dependence), as defined by DSM-IV criteria&#xD;
&#xD;
          -  Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV&#xD;
             criteria within 3 months prior to enrolment&#xD;
&#xD;
          -  Previous enrolment or randomisation of treatment in the present study.&#xD;
&#xD;
          -  Participation in another drug trial within 4 weeks prior enrolment into this study or&#xD;
             longer in accordance with local requirements&#xD;
&#xD;
          -  Medical conditions that would affect absorption, distribution, metabolism, or&#xD;
             excretion of study treatment&#xD;
&#xD;
          -  A patient with Diabetes Mellitus&#xD;
&#xD;
          -  An absolute neutrophil count (ANC) of &lt;= 1.5 x 10^9 per liter&#xD;
&#xD;
          -  Insomnia from other causes of medical or neurological diseases&#xD;
&#xD;
          -  Involvement in the planning and conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inkyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

